Theresa Natishan
Theresa Natishan is a director at Merck
Articles
Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based Approach
Frank Diana;Jeff Hofer;Marion Chatfield;Nancy Benz;Yuan Huang;Mark Argentine;Qinggang Wang;Shreekant Karmarkar;Hafez Abdel-Kader;Lakshmy M. Nair;Hui Fang;Theresa Natishan;Andrea M. Pless;Rick Burdick;Zeena Williams
October 2nd 2014A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: February 23rd 2024 | Updated: December 22nd 2024
Europa Perspectives: Helping to Navigate the Regulatory System
Published: December 13th 2024 | Updated: December 22nd 2024
FDA Creates CDER Center for Real-World Evidence Innovation
Published: December 5th 2024 | Updated: December 22nd 2024
Leveraging Advancements in Bioanalytical Testing
Published: December 7th 2024 | Updated: December 22nd 2024
Exploring Opportunities for LNP Delivery in mRNA
